ENDP up +4.04% percent Today $ENDP High is at 69.78 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 11:20 AM

ENDP up +4.04% percent Today $ENDP High is at 69.78 and the Low 67.14 with current volume of 514,637.

Recent News posted below.

Endo Pharmaceuticals Holdings Inc ENDP other info.
http://investorshangout.com/Endo-Health-Solut...NDP-54014/

ENDP Endo Pharmaceuticals Holdings Inc Recent Headline News

Endo International (ENDP) Strong On High Relative Volume Today
at The Street - 1 hr 18 mins ago
Trade-Ideas LLC identified Endo International (ENDP) as a strong on high relative volume candidate
ENDP: 69.56 (+2.50)

Endo Pharmaceuticals Earnings Hindsight: Down 3.6% in Last 12 Days (ENDP)
Comtex SmarTrend(R) - Mon Nov 17, 3:15PM CST
12 days ago, on November 5th, 2014, Endo Pharmaceuticals (NASDAQ:ENDP) reported its earnings. Analysts, on average, expected earnings of $0.99 per share on sales of $723.3 million. Endo Pharmaceuticals actually reported earnings of $1.15 per share on sales of $763.9 million, beating EPS estimates by $0.16 and beating revenue estimates by $40.6 million. Shares of Endo Pharmaceuticals have slipped from $68.70 to $66.26, representing a loss of 3.6%, since the company reported earnings 12 days ago.
ENDP: 69.56 (+2.50)

After Yesterday's Decline of 1.25%, Endo Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Nov 14, 4:38PM CST
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $66.00 to a high of $68.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $66.94 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 69.56 (+2.50)

Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo
PR Newswire - Mon Nov 10, 7:50AM CST
Today, Analysts Review released its research reports regarding Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), UnitedHealth Group Incorporated (NYSE: UNH), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Endo International plc (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7807-100free.
ENDP: 69.56 (+2.50), ACT: 261.20 (+13.26), JAZZ: 169.14 (-0.35), UNH: 98.43 (+1.96), CELG: 106.47 (+2.11), CELGZ: 3.18 (-0.03)

La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 69.56 (+2.50), LCI: 46.81 (+0.17), BCRX: 10.51 (+0.39), LJPC: 11.05 (+0.01)

Endo Receives Final Approval for Generic Version of Valcyte®
PR Newswire - Mon Nov 10, 7:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Qualitest subsidiary has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg).
ENDP: 69.56 (+2.50), ENL.TO: 75.76 (+0.61)

Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST

ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77)

Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST

ENDP: 69.56 (+2.50), RDY: 56.33 (+0.24)

Endo International Beats on Q3 Earnings & Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:30AM CST
Endo International's (ENDP) third-quarter 2014 earnings of $1.15 per share beat the Zacks Consensus Estimate.
AGN: 212.00 (+2.80), ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77), ABBV: 65.72 (+0.68)

Endo International's (ENDP) CEO Rajiv Kanishka Liyanaarchchie De Silva on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 12:50PM CST

ENDP: 69.56 (+2.50)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 108.49 (+1.69), ENDP: 69.56 (+2.50), AUXL: 32.95 (+0.77), SHPG: 208.72 (+2.73), DNDN: 0.17 (+0.02), SNSS: 2.21 (-0.10), ABBV: 65.72 (+0.68), SNY: 48.22 (+0.68), MNKD: 6.48 (+0.22), XOMA: 4.06 (+0.08)

Endo International (ENDP) Is Today's Water-Logged And Getting Wetter Stock
at The Street - Wed Nov 05, 9:29AM CST
Trade-Ideas LLC identified Endo International (ENDP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ENDP: 69.56 (+2.50)

Endo updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:18AM CST

ENDP: 69.56 (+2.50)

Endo International (ENDP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:55AM CST

ENDP: 69.56 (+2.50)

Endo beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:09AM CST

ENDP: 69.56 (+2.50)

Endo Reports Third Quarter Financial Results
PR Newswire - Wed Nov 05, 6:00AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today reported third quarter 2014 revenues of $764 million, an increase of 16 percent compared to third quarter 2013 revenues of $661 million. Endo reported a net loss of $252 million in the third quarter 2014 compared to net income of $40 million in the third quarter of 2013.
ENDP: 69.56 (+2.50), ENL.TO: 75.76 (+0.61)

Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST

MDLZ: 38.66 (+0.29), CSTE: 59.59 (+0.18), FSS: 15.44 (-0.10), HL: 2.51 (-0.03), BBEP: 15.11 (+0.10), RRD: 16.81 (-0.11), CNP: 24.47 (+0.09), INXN: 28.28 (unch), OGE: 36.93 (+0.24), MNTA: 10.90 (+0.30), GLDD: 7.19 (+0.12), AXAS: 3.93 (+0.02), MEMP: 16.32 (+0.20), PWE: 4.13 (-0.04), ROC: 79.10 (+0.02), SSYS: 105.40 (+1.24), DNR: 9.89 (-0.12), MVIS: 1.70 (+0.01), PWR: 33.32 (+0.15), COV: 97.65 (+3.04), SMG: 60.01 (+0.40), SEP: 56.82 (-0.28), CLH: 49.44 (-0.28), ATHM: 41.74 (-1.11), STWD: 23.57 (-0.03), BPI: 10.92 (+0.06), LVLT: 49.23 (+0.91), AVA: 34.22 (+0.43), MGA: 104.47 (+0.57), BSFT: 26.49 (-0.07), EE: 38.45 (+0.29), CTSH: 52.70 (-0.36), DAVE: 24.77 (+0.10), NRG: 31.97 (+0.29), CEQP: 8.64 (+0.24), ACT: 261.05 (+13.11), AWR: 34.54 (+0.14), DUK: 80.68 (+0.38), LAMR: 52.94 (+0.18), CCC: 20.88 (+0.02), HFC: 43.25 (+0.13), RTI: 23.59 (-0.02), CHK: 22.87 (-0.51), NUS: 39.46 (+1.18), NICE: 46.22 (-0.34), HRC: 45.49 (+0.30), ENDP: 69.56 (+2.50), SE: 38.47 (-0.01), CBB: 3.43 (+0.03), GTN: 10.06 (-0.03), ANSS: 80.50 (+0.77), RLGY: 43.17 (+0.35), ENB: 45.68 (+0.54), SBGI: 27.26 (-0.28), ARIA: 6.17 (+0.13), LPX: 14.80 (unch), RDC: 23.80 (-0.06), KELYA: 15.40 (+0.32)

Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 43.64 (-0.59), ENDP: 69.56 (+2.50), VRX: 141.23 (+4.50), PFE: 30.55 (+0.23)

Endo reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:03PM CDT

ENDP: 69.56 (+2.50)

Endo International plc (ENDPQ) Stock Research Links

ENDPQ Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ford Foundation Welcomes Gender Justice Leader Fatima Goss Graves

A Fresh Addition to Ford's Trustees Fatima Goss Graves steps into big shoes at the Ford Foundation as she gets appointed to its Board of Trustees. No small potatoes, this move suggests the Foundation's commitment to driving significant gender justice and advocacy. Add her name next to serious change-makers, folks, because Ms. Goss Graves is a heavyweight in the nonprofit...

Sarah Weede: A Force in Veterans Services Leadership

Saluting a Veteran's Advocate Amidst a world obsessed with bottom lines and market swings, it’s refreshing to spotlight someone like Sarah R. Weede. She's not about the Wall Street grind but you better believe her drive and dedication rival any big-shot CEO. Leadership in Veterans Services Sarah Weede's story starts with substantial roots planted in serving those who...

Tenet® Beef: Revolutionizing Tenderness in America's Steaks

Cracking the Code: A Genetic Leap in Beef Tenderness Well, buckle up, folks, because Callipyge Genetics is shaking things up in the beef aisle with their genomic breakthrough, Tenet®. It's about time we see some real innovation in an industry that's, let's face it, been slow to evolve. This isn't just a flash in the pan—a bit of DNA parsing has uncovered how to...

Spooky Suds: House of Horror Meets El Car Wash

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...

Alaska LNG Project Boosted by Strategic Positioning

Alaska LNG: Right Place, Right Time Someone bring out the confetti, because Paul Sullivan, Co-Chairman of Gastech, is celebrating Alaska LNG like it's 1999. And for good reason. If Alaska ever played its cards right, now's the moment according to the industry veteran. After Gastech 2026 wrapped its events in Bangkok last month, Sullivan laid out why the stars are aligning...

Florida Cancer Center Expands Expertise with New Oncologist

Welcoming a Highly Skilled Oncologist to Fort Myers There's an old saying in the world of investing: follow the expertise. And when it comes to healthcare, especially cancer treatment, expertise can make a world of difference. Florida Cancer Specialists & Research Institute (FCS) is throwing its hat in the ring with authority, as they welcome Dr. Kelly Elleson, a surgical...

Navigating Braces vs. Invisalign: Key Considerations

Choice Between Braces and Invisalign Isn't Straightforward When you're pondering over whether to go with braces or Invisalign, it ain't just a choice you make lightly over coffee. It's a nuanced decision that hinges on a multitude of factors as highlighted by orthodontic experts Dr. Erik Higginbottom and Dr. Kyle Higginbottom from Easton, MD, featured in HelloNation's...

Security Leadership Faces Unseen Identity Risks

Rocky Road in Identity Security Catch this: you're a security honcho, thinking you've forked over enough dough to lock down human and machine identities. But now, it turns out, most of your kind still don't have a full handle on who or what is poking around your systems. Talk about a wrench in the gears. This latest report from Oak drags the reality into the limelight:...

LBT Unveils Game-Changing Cyclotron for Medical Advances

Unveiling the LB-30 Cyclotron at EANM 2026 Life in nuclear medicine never stands still, and once again, Longevous Beamtech (LBT) is stirring the pot with its brand-new LB-30 series medical cyclotron. They rolled out this high-powered beast at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. Leaning into the 30 MeV energy...

Veteran Team Fuels Misunderstood Brands' Bold Expansion

Adding Heavyweights to Catalyze Growth Imagine you're Misunderstood Brands, prepping your artillery before charging into the battleground of national chains. What do you do? You double down strategically by rallying the best industry minds around. Announced on October 15, 2026, this company's concocted a dream team of beverage veterans as they steer their products—like...